Earnings Laine. First afternoon, Quarter to Call. and everyone, TransMedics welcome Good you, Thank XXXX
our Gordon, Chief Stephen is today me joining Financial always, As Officer.
XXXX X crucial transformational For not revenue our further also for delivered increased product drive while only past represents broadening to pipeline another TransMedics years, has but exceptional growth profitability volumes. importantly, business. transplant year and for growth, and infrastructure making the our in investments growth, exceptional
we focused NOP build-out initial X phase completing and Specifically, transplant overall second, U.S.; our of accelerate and Heart the the adoption clinical expand for growing further new infrastructure; first, aviation clinical and OCS OCS and verticals: volumes for our national fleet programs logistics indications OCS on Heart are program. finally, the transplant our the one-of-a-kind to X TransMedics of preparing even major launch Lung through in
$XX.X representing quarter repeat, any transplant from Said growth. the logistics of QX revenue and that million, for we up logistics logistics across to these growth well growth QX QX $X.X QX the to first representing to in through On transplant for grew our million This growth product last over Total our every the year, highlight approximately representing growth heart very expect growth XXXX. was as With a the OCS quarter-over-quarter. by $XX.X million, adoption.
TransMedics service.
I differently, momentum a front, key increased XXX% growth business, logistics our from as nature achieved of QX want both increased XXXX and utilization liver TransMedics for XX% be and future fully transplant only we lung, review transplant sequential was results highlights have towards strong for new revenue product growth both overwhelmingly dispel achieving high goals. XX% with potential me driven started to -- watermark year let service our revenue by of fully driven diversified is XQ I expect misperception performance. we
logistics and delivering for TransMedics service cost continuing programs capabilities on are demonstrate real operational to to across our which further the logistics NOP value integrated today. XXXX, presentation in focused We and our infrastructures expanding U.S. such are remain TransMedics throughout that We I the is later transplant detail efficient, will
gross XX% Our last up margins XX%, in line expectations. with QX our and from for quarter was overall
we are service We the scale $XX.X both the represents income to us be GAAP was will able XX% in XX operating margins $XX.X enabled and more Net over total extremely growth million, profit of XX leverage to which product strong of confident as next that we achieve margin gross improve further revenue. to gross months revenue in and deliver of million. operations.
The
in operating these cash delivering quarters. heavily future are still the metrics flow growth. profitability achieved laser while proud We however, remain next over to We investing focused, on very have positive sustainable several
financial Before to achieve recognize our -- moment beyond performance, our to on has had like a take worked team, momentum the which to I'd these entire to which TransMedics results. tirelessly moving
to upon on We execution the QX build are focused result.
Now more with that across let background, me metrics. key detail operating provide
markets new organ will X QX. NOP watermark case volume remains case our a trend expect a XX-plus high of stated we across I which throughout future. the we foreseeable contribution As for set in percent at volume, continue Overall, above, all
Turning in daily X metrics. now by active Through QX TransMedics of to of Meanwhile, quarter. QX owned expand to X number XXXX. fleet XX the in compared the planes aircraft owned key continue average end to our planes aircraft aviation of the were QX, TransMedics we reaching transplant logistics of
year-end. to increase XX number reach continue this XX by throughout aircraft to expect the We we year as to operational will strive
and in transplant covered of missions This underscores across 'XX. in our additional runway to Our QX operations. to NOP efficiency XX% further flight the XX% potential long compared logistics owned aircraft QX our of growth approximately maximizing drive
total scale, ground missions logistics for both the to stated cover services of expect we at transport. air we using fully NOP percent and TransMedics our XX-plus before, As
QX, used safe compared In approximately missions.
From in services. to a are the approximately transplant logistics QX We transplant that will carefully to continue of to also highly continued U.S. additional to lifts XX XXXX. supplemental we XXX grow programs number reliable footprint of and our use selected, support our customer perspective, operators have using programs logistics for TransMedics
and rapidly of needs reliability more efficiency transplant are throughout programs logistics their compared As now and year that XXXX we the operations. deeper we of mass forward.
Overall, with TransMedics are transplant are confident logistics air as we of have We cost our users, are the going within success further services significant our historical and forward this and very early critical of logistics transplant the expanding programs on and meeting we model. to fleet achieved seeing focusing ground pleased look to into scale these going
outcomes evidence clinical We this in are transplant also encouraged We as this experts, Lung Heart real-world from Society several and demonstrating OCS in Prague. growing OCS excitement value of around excitement Transplant firsthand of attended were At the users. of International by base we of the meeting, saw presentations Lung offering presented. clinical Heart by the scientific and across year April and the academic growing transplant our Conference our
that to Heart recipients. NRP. demonstrated compared to This transplants also OCS from registry outcomes with evidence OCS DCD better all Here OCS DCD have DCD high-risk data transplants OHP key Jacob donor patient Heart highlights.
Dr. Heart heart at affords of this demonstrated the are survival provided DCD The in protection U.S. NRP provides the transplants that OHP, approximately heart in Duke OCS The registry heart Schroder as data presented evidence the was compared centers. experience X/X the of transplanted -- superior DCD in that Perfusion, hearts or used
During when costs. clinical Dr. favorable and of NOP the hardware his costs the overhead presentation, that Schroder dry cost more the OCS cost in to overall support commented is the NRP factoring runs,
the NOP giving clinical donor OCS heart the in that highlighted for patients or heart procurement costs the enhances management Schroder to burden by of Dr. curves service of overhead unified any standard DCD and program transplant Importantly, to the learning the U.S. NOP transplantation clinical the staff. offer their TransMedics of hearts ability and without the
transplant showed cross-clamp the The to despite data criteria also U.S. time. OCS This Next, OCS the standard in has DCD Medical worst, transplants. Dr. heart led OCS PGD moderate higher U.S. showed early from the been after to long-term compared broader had PGD, is most the severe short- double were and similar similar DBD of have signifies standard significant with graft the OCS NOP. to Emory OCS the clinical presented validates heart reduction transplant transported transplant best to and profile afforded that to and care in patient survival. Heart.
Simply in DCD or U.S. complication the This Daneshmand dysfunction, of Daneshmand primary OCS the distance has outcomes risk of NOP hearts donors factors, were DBD national donor DBD DCD University double Severe use access heart survival stated, of recipients the to outcomes enabled the Center Dr. clinical in the a the also data OCS to safety are hearts increased which DCD DCD the and highlighted The that donor world. Mani that nearly from OCS further historically by outcomes associated the post-heart severe outcomes, outcomes
preserved experience outcomes presented criteria resulted by distance NOP. validates storage access Villavicencio Xx in in registry. The travel distant for NOP NOP Again, compared Heart the donors OCS DBD afforded Next, that data donors from and the arm. to the cold workflow cross-clamp potential Dr. OCS Mauricio having longer clinical and showed broader despite Mayo static standard double from OCS OCS with post-transplant OHP Clinic the donors time data to this improved the the from excellent DBD
and Gabe Next, over of from years standard using OCS post for the compared donor criteria lung at results. support lungs criteria at chronic same huge program DBD DBD showed survival from Dr. extended DCD transplanted Baylor trial lung and Lung Loor and donors from time that the DBD X-year clinical results expand routine, clinical transplants freedom The period. Lung the the utilization in potential U.S. had expand transplant Luke's These the criteria data to presented OCS increasing similar same the extended donors DCD St. rejection X
the again in OCS by having DCD lungs clinical our DBD Finally, criteria as data well of and the pool the once donor resulted survival from potential Lung enabled Minnesota and standard Huddleston and further validating data of clinical expanding shared and body highlighted similar Steve outcomes The showed criteria extended volumes positive from U.S.
Collectively, the ever-growing the enabled registry. time, that are impact post-transplant perfusion TOP OCS lung to the these transplant registry, huge nearly use donors NOP. exceptional the the clinical in the Dr. on OCS of growth latest despite presentations the as thoracic evidence lung or University donor outcomes from that transplant double cross-clamp the again, of
the shift further. Now our adoption and let further and plans overall volumes OCS national gears grow even transplant about talk to me U.S.
our expand X to major as programs FDA indications discuss Lung next OCS year. OCS we U.S.
Pending OCS new within our FDA to want clinical clinical Heart initiate that as the enrollment of I Heart will programs approval, all designed Specifically, in adoption grow expect and the well X
OCS Let program. me Lung start detailing the with
the Lung their As perfusion assessment. many post-transplant potential United NOP ability believe transplant to stated increase stakeholders market times, specifically, we the underappreciated. positive believe clinical OCS of clinical OCS to and that clinical States their of be value transplant Lung across workflow lung we reintroduced the we the the and improve enhanced to need remain outcomes and More the volumes,
to morning Liver and clinical that is we and following. and compared transplant goal launch in to of OCS programs their outcomes overall successful OCS middle night to enable firsthand while to replicating the to programs the done improving value replicate this, differently, NOP hours volumes growing are with we're transplant their post-transplant achieved planning Lung.
Said NOP at now volumes lung transplants want the where experience achieve Our OCS outcomes. new do XX% OCS and with To a the of to transplant of surgeons morning the program the have clinical clinical working
of will First, transplant hours to the staff. lung OCS to minimum XX- for target using perfusion and a NOP transplantable access increase of optimize work program to model plus donor XX-hour we Lung
assess storage Importantly, we clinical to value. aim to prospectively cold static controlled NOP a randomize versus OCS between
and of perfusion developed times near newly concerns OCS combined lung perfusion with impact on solution use eliminate edema minimize perfusion longer to lung clinical any potentially function. to lung plan also blood the on physiologic of We
We prolonged will modality and also maximize and ventilation vivo use perfusion ventilation. the circuitry during protection to ex next-gen donor lungs for OCS perfusion the
the enrollment entire rate From program be the timing increase a to XXXX. of the expect around initiation phase. end during NOP program are targeting of adoption we We the perspective, clinical managed by trial of this sometime and to
planned Heart move let Now programs. me on to OCS our
in NOP are actively model. on managed distinct We large working will Heart OCS the that be also X exclusively OCS via the programs also U.S.
volumes transplant aimed at XX-hour warm to and of NOP heart using the the to This for OCS working increase optimize in therapeutic program model DBD Heart from utilization of increase plus hearts OCS transplant is intend standard criteria perfusion hours increasing We hearts overall perfusion the is both first hearts. The for Heart extended donors staff. to program and target access the donor U.S. to our DBD
a OCS also randomize use OCS of but will adding to assess timing the storage with value. agents we're protection clinical donor perspective, of combined targeting not proprietary initiation heart aim a prospectively end the new only NOP improve developed versus its We're are cold sometime to near-physiologic We around our blood, performance. to solution newly in the of program, controlled we to planning this metabolic-enhancing and therapeutic some maximize program post-transplant XXXX. this clinical static From particular perfusion
clinical cold a to the from up. DBD a specifically, oxygenated utilizes hearts oxygenated blood-based that for portable hours. perfusion a in offer system controlled program technology OCS a less designed program. -- pulsatile, to a which aim within our assess to Again, this, To XXXX program hearts less indications storage allow are is use heart that circuitry new perfusion preserved X the and we we'll than randomize require And to clinical OCS new is criteria product NOP support model. important easy-to-use do planning prospectively standard perfuse value. cold cold clinical are cold second static for lower-cost cold new aiming for in perfusion to targeting More U.S. our for that we're It's controlled Heart new for not Heart achieve X at DBD technology us will cold new program hours, ground technology. this our to developing that fully U.S. to the early to perfusion existing our preserve initiate Finally, the clinical indication This we're is FDA than current and will
are pipeline overall case we national the see, OCS drive can transplant programs you in U.S. clinical very to designed As the of and in strong advancing significant growth cardiothoracic a volume volume
stopping However, we're here. not
will all initiative We NOP to products to share our to are year.
To deliver also We organs for in encouraged care propel invest workload OCS heavily the streamline platform performance this automated, several technology to details highly that be for of -- all our and summarize, more X better workflow we services. the quality product next-gen achieve clinical X for and are continuing QX to highest continue highly by to leverage. further focused clinical for plan support designed and to this us optimized TransMedics on later and on are initiatives designed growth allow
year XX% the million are the that, $XXX annual full results Given cover increasing to in represents QX, performance quarter. our over for growth to our guidance million, $XXX detailed to the we strong Stephen to XX% to revenue turn me financial XXXX which let revenue.
With call
